Neonatal atypical hemolytic uremic syndrome from a factor H mutation treated with eculizumab

Clinical Nephrology

Volumn 84, Issue 3, 2015, Pages 181-185

  Sharma, Sheena ^a   Pradhan, Madhura ^a   Meyers, Kevin E C ^a   Le Palma, Krisha ^a   Laskin, Benjamin L ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Atypical hemolytic uremic syndrome (aHUS); Neonates

Indexed keywords

AMPICILLIN; C REACTIVE PROTEIN; COMPLEMENT FACTOR H; CREATININE; DOBUTAMINE; ECULIZUMAB; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEMOGLOBIN; LACTATE DEHYDROGENASE; MILRINONE; NITROGEN; PENICILLIN V POTASSIUM; PNEUMOCOCCUS VACCINE; PROPRANOLOL; TETANUS TOXOID; UREA; MONOCLONAL ANTIBODY;

ACUTE RESPIRATORY FAILURE; ARTICLE; BIRTH WEIGHT; BLOOD PRESSURE; CASE REPORT; CREATININE BLOOD LEVEL; DAY HOSPITAL; DOPPLER FLOWMETRY; ECHOCARDIOGRAPHY; ERYTHROCYTE TRANSFUSION; EXON; FEMALE; GENE MUTATION; GENETIC SCREENING; GESTATIONAL AGE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPOTHERMIA; INTUBATION; LABORATORY TEST; MISSENSE MUTATION; NEWBORN; NEWBORN DISEASE; OLIGURIA; PERITONEAL DIALYSIS; PLASMA TRANSFUSION; PLASMAPHERESIS; PROTEIN URINE LEVEL; SEPSIS; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; UREA NITROGEN BLOOD LEVEL; URINALYSIS; ATYPICAL HEMOLYTIC UREMIC SYNDROME; GENETICS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT FACTOR H; FEMALE; HUMANS; INFANT, NEWBORN;

EID: 84944051531     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN108532     Document Type: Article

References (18)

1. Michaux K, Bacchetta J, Javouhey E, Cochat P, Frémaux-Bacchi V, Sellier-Leclerc AL. Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency. Pediatr Nephrol. 2014; 29: 2415-2419. CrossRef PubMed
2. Besbas N, Gulhan B, Karpman D, Topaloglu R, Duzova A, Korkmaz E, Ozaltin F. Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab. Pediatr Nephrol. 2013; 28: 155-158. CrossRef PubMed
3. Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, Dixon BP, Teusink A, Pluthero FG, Lu L, Licht C, Davies SM. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2014; 20: 518-525. CrossRef PubMed
4. Lapeyraque AL, Frémeaux-Bacchi V, Robitaille P. Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol. 2011; 26: 621-624. CrossRef PubMed
5. Ariceta G, Arrizabalaga B, Aguirre M, Morteruel E, Lopez-Trascasa M. Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am J Kidney Dis. 2012; 59: 707-710. CrossRef PubMed
6. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012; 8: 643-657. Cross-Ref PubMed
7. Gilbert RD, Fowler DJ, Angus E, Hardy SA, Stanley L, Goodship TH. Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gainof-function mutation of complement factor B. Pediatr Nephrol. 2013; 28: 1315-1318. CrossRef PubMed
8. Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis. 2014; 64: 633-637. CrossRef PubMed
9. Lexicomp (eculizumab) 2015. http://www.crlonline. com/lco/action/doc/retrieve/docid/pat ch_f/810198. Accessed January 6, 2015.
10. Saland J. Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab? Pediatr Nephrol. 2014; 29: 329-332. CrossRef PubMed
11. Trumenba® (meningococcal group B vaccine) [package insert]. Pfizer, INc.; Revised October, 2014.
12. Soliris® (eculizumab) [package insert]. Cheshire CAP, Inc.; Revised April, 2014.
13. American Academy of Pediatrics. Primary and Secondary Immune Deficiencies. In: Pickering LK BC, Kimberlin DW, Long SS, eds. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Illinois: American Academy of Pediatrics; 2012: p. 78-81.
14. Ohta T, Urayama K, Tada Y, Furue T, Imai S, Matsubara K, Ono H, Sakano T, Jinno K, Yoshida Y, Miyata T, Fujimura Y. Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension. Pediatr Nephrol. 2014; epub ahead of print. CrossRef PubMed
15. Kim JJ, Waller SC, Reid CJ. Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysis. Clin Kidney J. 2012; 5: 34-36. CrossRef
16. Giordano M, Castellano G, Messina G, Divella C, Bellantuono R, Puteo F, Colella V, Depalo T, Gesualdo L. Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report. Pediatrics. 2012; 130: e1385-e1388. CrossRef PubMed
17. Centers for Disease Control and Prevention. Recommended immunization schedule for persons aged 0 through18 years. Immunization Schedules home page. http://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html. Published January 31, 2014, Accessed November 10, 2014.
18. American Academy of Pediatrics. Meningococcal Infections. In: Pickering LK BC, Kimberlin DW, Long SS, eds. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Illinois: American Academy of Pediatrics; 2012: p. 500-509.